Google
SMMT — SUMMIT THERAPEUTICS PLC (Healthcare >> Biotechnology)
SMMT FAQ
What is SMMT's ROE?
SUMMIT THERAPEUTICS PLC reports a Return on Equity (ROE) of -210.67%.
What is SMMT's dividend yield?
SUMMIT THERAPEUTICS PLC offers a dividend yield of 0.00%.
What is SMMT's Deepscope Quality Score?
Deepscope rates SMMT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SMMT?
Deepscope's AI Timing Score for SMMT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SMMT belong to?
SUMMIT THERAPEUTICS PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 14.29
Price
0.18
(1.28%)
Day Change
|
|
|---|
SMMT, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.29 |
| PBV / Sector |
26.45 / 4.71
|
| Earning Per Share | -1.14 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
83.85 M
|
| Average 1W Daily Value |
77.55 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
47% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:54 |
| Symbol | SMMT |
| Name | SUMMIT THERAPEUTICS PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 776.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10,951.65 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 601 Brickell Key Drive, Miami, FL, United States, 33131
Phone: 305 203 2034
Website: https://www.smmttx.com
Employees: 265
Sector: Healthcare >> Biotechnology
Description: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
